Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OmnImmune (TCB-002) in Relapsed/Refractory AML
NCT03790072Phase 1Completed
- Sponsor
- TC BioPharm
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TCB008 in acute myeloid leukemia (AML), sponsored by TC BioPharm. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at Day 28 and Incidence of Dose-Limiting Toxicities at Day 28. Started Nov 2018; status: completed.
02
Drugs
TCB008
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03790072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790072.